Literature DB >> 8642276

Human tumor antigens recognized by T lymphocytes.

T Boon1, P van der Bruggen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8642276      PMCID： PMC2192342          DOI： 10.1084/jem.183.3.725

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


× No keyword cloud information.
  59 in total

1.  Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit.

Authors:  C A Lancaster; N Peat; T Duhig; D Wilson; J Taylor-Papadimitriou; S J Gendler
Journal:  Biochem Biophys Res Commun       Date:  1990-12-31       Impact factor: 3.575

2.  Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

Authors:  C Lurquin; A Van Pel; B Mariamé; E De Plaen; J P Szikora; C Janssens; M J Reddehase; J Lejeune; T Boon
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

3.  Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis.

Authors:  G G Haas; O J D'Cruz; L E De Bault
Journal:  Am J Reprod Immunol Microbiol       Date:  1988-10

4.  Human tumor-specific cytotoxic T cell lines generated from tumor-draining lymph node infiltrate.

Authors:  D L Barnd; L A Kerr; R S Metzgar; O J Finn
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

5.  Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

Authors:  J M Richards; N Mehta; K Ramming; P Skosey
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

6.  Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.

Authors:  P F Robbins; M el-Gamil; Y F Li; S L Topalian; L Rivoltini; K Sakaguchi; E Appella; Y Kawakami; S A Rosenberg
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

7.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

8.  Prognostic significance of hypopigmentation in malignant melanoma.

Authors:  J C Bystryn; D Rigel; R J Friedman; A Kopf
Journal:  Arch Dermatol       Date:  1987-08

9.  A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.

Authors:  S Gendler; J Taylor-Papadimitriou; T Duhig; J Rothbard; J Burchell
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

10.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Authors:  B Van den Eynde; B Lethé; A Van Pel; E De Plaen; T Boon
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307
View more
  148 in total

Review 1.  Heat shock proteins: the fountainhead of innate and adaptive immune responses.

Authors:  S Basu; P K Srivastava
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

2.  Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Authors:  S J Pettit; S Ali; E O'Flaherty; T R Griffiths; D E Neal; J A Kirby
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 3.  New methods for assessing T-cell responses.

Authors:  N Bercovici; M T Duffour; S Agrawal; M Salcedo; J P Abastado
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

4.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.

Authors:  E M Tan
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 5.  Benign autoimmunity to combat malignancy.

Authors:  H J Stauss
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

6.  Progress in cancer vaccines by enhanced self-presentation.

Authors:  S R Riddell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

7.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

8.  [Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy].

Authors:  Antje Neumann; Julia Karbach; Akin Atmaca; Elke Jäger
Journal:  Med Klin (Munich)       Date:  2010-04

9.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors:  E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

10.  A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.

Authors:  Yan Yan; Leuyen Phan; Fan Yang; Moshe Talpaz; Yu Yang; Zeyu Xiong; Bernard Ng; Nikolai A Timchenko; Catherine J Wu; Jerome Ritz; Hong Wang; Xiao-Feng Yang
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.